Physiomics hits 52-week high on study outcome

1st Apr 2011 16:11

The Oxford based systems biology company Physiomics said positive results have been generated in a pre-clinical study into breast cancer based on the company's "Virtual Tumour" model predictions. The directors believe these results provide further validation as to the predictive capability of the company's technology. Dr Mark Chadwick, chief executive officer of Physiomics, said: "We believe that the optimal clinical scheduling for these drugs is still an open question and that our rational approaches could help to resolve it. To the best of our knowledge, this is the first time that modelling has been used to provide such a dramatic improvement response with these two drugs in a xenograft study."A xenograft is a surgical graft of tissue from one species to an unlike species.ab